News & Updates

Lenvatinib + pembrolizumab combination regimen improves progression-free survival (PFS) compared with sunitinib in a subset of East Asian patients with advanced renal cell carcinoma (aRCC), a finding that was similar to that of the global population of the CLEAR* trial, according to a subanalysis presented at ASCO GU 2022.

Asian and Hispanic oncologists, as well as female oncologists treating genitourinary malignancies, receive lower patient satisfaction scores (PSS), according to a study.

Salvage chemotherapy is preferable over surgery in patients with alpha-fetoprotein (AFP) >30 µg/l and human chorionic gonadotropin (HCG) ≥20 mIU/ml after first-line chemotherapy, suggests a study.

Eleven different malignancies seem to be correlate with metabolic syndrome (MS), as well as with the presence of MS components, reports a recent study.

Neoadjuvant chemotherapy may lead to worse overall survival in women who had undergone mastectomy and immediate breast reconstruction, a recent study has found.

The rates of positive surgical margin (PSM) with Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) are acceptable and higher in pT3 disease than in pT2, according to a study.

First-line treatment with pembrolizumab + chemotherapy maintains overall survival (OS) and progression-free survival (PFS) in patients with advanced or metastatic oesophageal cancer, according to an additional 12-month follow-up of the KEYNOTE-590* study presented at ASCO GI 2022.